Product Description
Shattuck’s lead DR3 blocking antibody, SL-325, demonstrates superior inhibition and efficacy in preclinical assays over therapies targeting TLIA. SL-325 harnesses the power of high affinity, epitope specificity and critical Fc-silencing to block TLIA from engaging DR3 expressed on multiple immune cells that drive inflammation. From our scientific expertise in protein engineering, we have advanced SL-325, a first-in-class DR3 antagonist. Our preclinical studies demonstrate high affinity binding, superior efficacy over TLIA antibodies, and offer a data-driven rationalization for targeting the TNF receptor, DR3, versus its ligand, TLIA. (Sourced from: https://www.shattucklabs.com/our-science/sl-325/)
Mechanisms of Action: DR3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shattuck Labs
Company Location: AUSTIN TX 78703
Company CEO: Taylor Schreiber
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Inflammatory Bowel Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|